Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785003 | 0.92 | PTGDR2 (0.56) | PTGDR2CYP2C9PTGDRAKR1B1 | |
| SCHEMBL5749192 | 0.87 | PTGDR2 (0.60) | PTGDR2CYP2C9PTGDRAKR1B1 | |
| SCHEMBL1787716 | 0.87 | PTGDR2 (0.64) | PTGDR2CYP2C9PTGDRAKR1B1 | |
| SCHEMBL1788163 | 0.85 | PTGDR2 (0.66) | PTGDR2CYP2C9PTGDRAKR1B1 | |
| SCHEMBL5739375 | 0.83 | PTGDR2 (0.55) | PTGDR2CYP2C9PTGDRAKR1B1 | |
| SCHEMBL1786162 | 0.82 | PTGDR2 (0.62) | PTGDR2CYP2C9PTGDR | |
| SCHEMBL1782692 | 0.78 | PTGDR2 (0.72) | PTGDR2 | |
| SCHEMBL2088388 | 0.75 | PTGDR2 (0.52) | PTGDR2CYP2C9PTGDRAKR1B1 | |
| SCHEMBL27645796 | 0.74 | PTGDR2 (0.53) | PTGDR2CYP2C9PTGDRAKR1B1 | |
| SCHEMBL19361446 | 0.74 | PTGDR2 (0.63) | PTGDR2CYP2C9PTGDRAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305879-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED (INDOL-1-YL)-ACETIC ACID ESTERS | ZACH SYSTEM SPA (IT) | 2017-10-26 | — | — | US | claimed |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | claimed |
| US-20130052190-A1 | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions | OXAGEN LIMITED (GB) | 2013-02-28 | — | — | US | claimed |
| US-8314257-B2 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2012-11-20 | — | — | US | claimed |
| US-8198314-B2 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2012-06-12 | — | — | US | claimed |
| US-8163936-B2 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2012-04-24 | — | — | US | claimed |
| US-8163931-B2 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2012-04-24 | — | — | US | claimed |
| US-20110124683-A1 | Use of CRTH2 Antagonist Compounds | OXAGEN LIMITED (GB) | 2011-05-26 | — | — | US | claimed |
| EP-2219645-A2 | USE OF CRTH2 ANTAGONIST COMPOUNDS | Oxagen Limited (GB) | 2010-08-25 | — | — | EP | claimed |
| US-7582672-B2 | Compounds for the treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2009-09-01 | — | — | US | claimed |
| EP-1682121-B1 | USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY | OXAGEN LTD (GB) | 2009-08-12 | — | — | EP | claimed |
| WO-2009063202-A2 | USE OF CRTH2 ANTAGONIST COMPOUNDS | OXAGEN LIMITED (GB) | 2009-05-22 | — | — | WO | claimed |
| EP-2060258-A1 | Use of CRTH2 antagonist compounds in therapy | Oxagen Limited (GB) | 2009-05-20 | — | — | EP | claimed |
| US-20090018138-A1 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2009-01-15 | — | — | US | claimed |
| US-20090018139-A1 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2009-01-15 | — | — | US | claimed |
| EP-1682121-A1 | USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY | Oxagen Limited (GB) | 2006-07-26 | — | — | EP | claimed |
| US-20050119268-A1 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2005-06-02 | — | — | US | claimed |
| WO-2005044260-A1 | USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY | OXAGEN LIMITED (GB) | 2005-05-19 | — | — | WO | claimed |
| EP-3083557-B1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED (INDOL-1-YL)-ACETIC ACID ESTERS | ATOPIX THERAPEUTICS LTD (GB) | 2017-11-29 | — | — | EP | disclosed |
| US-20050119268-A1 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018138-A1 | Treatment of CRTH2-mediated diseases and conditions | PTGDR2, PTGER2, PTGES2 | PTGDR2 1/4885CYP2C9 3770/4885PTGDR 4/4885 |
| US-20050119268-A1 | Treatment of CRTH2-mediated diseases and conditions | PTGDR2, PTGER2, PTGES2 | PTGDR2 1/4885CYP2C9 3770/4885PTGDR 4/4885 |
| US-20090018139-A1 | Treatment of CRTH2-mediated diseases and conditions | PTGDR2, PTGER2, PTGES2 | PTGDR2 1/4885CYP2C9 3770/4885PTGDR 4/4885 |
| US-20110124683-A1 | Use of CRTH2 Antagonist Compounds | HRH2, HRH1, HRH4 | PTGDR2 25/4885CYP2C9 2730/4885PTGDR 47/4885 |
| US-20130052190-A1 | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions | HRH2, HRH1, HRH4 | PTGDR2 58/4885CYP2C9 3419/4885PTGDR 119/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | PTGDR2 59/4885CYP2C9 2737/4885PTGDR 108/4885 |
| US-20170305879-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED (INDOL-1-YL)-ACETIC ACID ESTERS | IDO1, IDO2, SI | PTGDR2 1790/4885CYP2C9 910/4885PTGDR 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.